Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: RTOG 1016 - A PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VERSUS CHEMORADIOTHERAPY IN HPV-ASSOCIATED OROPHARYNX CANCER

 


RTOG 1016 - A PHASE III TRIAL OF RADIOTHERAPY PLUS CETUXIMAB VERSUS CHEMORADIOTHERAPY IN HPV-ASSOCIATED OROPHARYNX CANCER


Trial Focus

Head and Neck Cancers

Objective

         The purpose of this study is to compare the effects, good and/or bad, of two standard treatments for head and neck cancer: radiation therapy and cisplatin or radiation therapy and cetuximab.

IRB Protocol #

12-0414

Trial Status

Archived

Principle Investigator

DAVID RABEN

Sponsor

RTOG

Contact

ROBYN SWING at (720)848-0607 or ROBYN.SWING@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Dept Of Veterans Affairs Medical Center ST. MARYS HOSPITAL - G.J. University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. Group 1 patients will receive radiation therapy for about 6 weeks and study drug A on days 1 and 22 during radiation. Group 2 patients will receive a dose of study drug B a week before radiation. If the tolerate study drug B well, they will receive study drug B once a week for 6 weeks during radiation therapy, and once after radiation therapy. A follow up period will consist of clinic visits after one and three months of treatment, every three months two years after treatment, every six months three years after treatment, and once a year for the rest of their lifetimes. // Eligibility criteria include but are not limited to 18 years or older, with HPV-associated oropharynx cancer.Eligibility criteria include but are not limited to 18 years or older, with HPV-associated oropharynx cancer.